Oral Coenzyme Q10 Supplementation In Patients With Migraine: Effects On Clinical Features And Inflammatory Markers
Notes for this study:
||(ng/ml). Geometric mean and Minimum-Maximum. Placebo: before 12.57 (7.70–58.00), after 13.14 (7.27–65.70). Intervention: before 17.02 (7.62–59.00), after 14.87 (7.32–49.70).
|Number of Subjects
In a randomized, double-blind, placebo-controlled trial, 45 premenopausal women with episodic migraine were allocated to take 400 mg of coq10 daily or placebo for 3 months.
Migraine frequency, severity, and duration were all reduced significantly more than placebo. Calcitonin gene-related peptide and tumor necrosis factor were reduced significantly more in the coq10 group, while IL-6 was reduced nonsignificantly more, and IL-10 increased nonsignificantly more.